2023 annual financial data

Inhibikase Therapeutics 2023 Financial results

Direct answer

Revenue was 260,500 USD.

Operating income was -20.09M USD and net income was -19.03M USD.
Operating cash flow was -18.09M USD.

Get free Inhibikase Therapeutics email updates.

Bullstory sends one daily email when new analysis or important company news is available.

Verified data

Revenue
260,500 USD
Operating income
-20.09M USD
Net income
-19.03M USD
Operating cash flow
-18.09M USD